Nick Chen

Vice President
Applied BioCode Corporation

​

In charge of Applied BioCode Taiwan subsidiary office.
Oversees supply chain for core technology platform, manages contract manufacture, and is responsible for Investor Relation.
It is my mission, to help business partners succeed with Applied BioCode’s multiplex technology, and together achieve better patient result and better health.

 

Speech title & Synopsis

Company Profile

Applied BioCode Corporation (ABC-KY, 6598) is an IVD diagnostic company that designs, develops, and commercializes multiplex testing products.  The company has pathogen reagents and instrument that receive US-FDA approvals, and recognition from world class lab customers in both human and animal health.  The company has a business focus in high throughput and reimbursable diagnostics market, and has penetrated several US national labs.  With increasing adapted labs number and continuous reagent products rollout, the company is set to make a name in the pathogen diagnostics domain.    
The core technology platform, Barcoded Magnetic Bead (BMB) is a novel “digital micro barcode” that combines with immuno- and molecular chemistry, which enable unparallel multiplex capability for diagnostic products. 
The company expects to extend its application into cancer diagnostics, as the BMB technology is a great fit for traceable, affordable, and actionable tumor liquid biopsy, which has been demonstrated in a small volume comparison study with current industry practice.
The company is listed on the Taiwan Stock Exchange.